EGFR and metastatic neoplasm: However, the overall frequencies of actionable alterations were comparable to those reported by Skoulidis and Heymach [30] for metastatic rather than early-stage disease with the exceptions of ALK alterations that were close to those reported for early-stage disease, and EGFR that falls between those reported for early and metastatic disease.